Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00038441 · ClinicalTrials.gov registry record · Phase 1
Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT00038441: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00038441 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 39 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00038441, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
This is a clinical research study of a new investigational treatment for cancer called "DTI-015" to be given by intratumoral injection. Intratumoral injection is when drug is injected directly into the tumor. This study will help doctors find out what is the best dose level for DTI-015 and if this treatment can shrink tumors without causing severe side effects. The effects of the drug on the patient's quality of life (how the patient feels and what the patient can do) and their mental functions (reasoning and thinking abilities) will also be studied.
Interventions
- DRUG DTI-015
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 1995-09 |
| Est. Completion | 2005-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00038441
The ClinicalTrials.gov registry entry for NCT00038441 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DTI-015 is the first listed.
NCT00038441 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00038441 about?
NCT00038441 is a clinical study titled "Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas". This is a clinical research study of a new investigational treatment for cancer called "DTI-015" to be given by intratumoral injection. Intratumoral injection is when drug is injected directly into the tumor. This study will help doctors find out what is the best dose level for DTI-015 and if this t...
What is the current status of trial NCT00038441?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 1995-09. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00038441?
The interventions under investigation include: DTI-015 (DRUG).
Who is sponsoring clinical trial NCT00038441?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.